Mission Therapeutics Ltd.

https://www.missiontherapeutics.com

LinkedIn: https://www.linkedin.com/company/mission-therapeutics

Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria, promoting cell health and function. Mitochondria are energy producing organelles which require lifetime quality control through a ubiquitin-mediated clearance mechanism known as mitophagy. In certain situations, such as cellular stress, cell injury, and/or defects of the mitophagy process, the mitochondria can become dysfunctional and damaging to the cell, leading to reduced energy production, oxidative stress, inflammation and potentially cell death. Dysfunctional mitochondria are significant drivers of disease pathophysiology in acute kidney injury (AKI), Parkinson’s Disease (PD), heart failure, Duchenne’s Muscular Dystrophy, IPF, mitochondrial diseases and Alzheimer’s. USP30 is a deubiquitylating enzyme that constantly removes ubiquitin from mitochondria, providing a potential brake on clearance of dysfunctional mitochondria. Mission is currently developing two small molecule drugs, MTX652 (peripheral) and MTX325 (targeting the CNS) which, through inhibition of the mitochondrial DUB enzyme USP30, will promote clearance of dysfunctional mitochondria – consequently improving overall cellular health. Mission’s USP30 inhibitors MTX652 and MTX325 could potentially be used to treat any disease or condition driven by mitochondrial dysfunction. Mission is backed by blue chip investors including Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital. *

	Start	2011-08-25 existent
	Predecessor	Cancer Research UK (CRUK) (Group)
	Industry	MTX325 (USP30 inhibitor) (Mission Therapeutics)
	Industry 2	small-molecule cancer drug
	Person	Lundemose, Anker (Mission Therapeutics 201501– CEO before Bionor Pharma + OSI Pharma + Prosidion + Novo Nordisk)
	Person 2	Wallace, Paul (Mission Therapeutics 201503– CBO before Medivir AB Head of Business Development)

	Region	Babraham, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Glenn Berge Building, The Babraham Research Campus
	City	CB22 3FH Babraham, Cambridgeshire
	Tel	+44-1223-607340
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Mission Therapeutics Ltd.. (7/2/24). "Press Release: Mission Therapeutics Awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325". Cambridge.

		Record changed: 2025-03-16